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ABSTRACT
Objective: The objective of this study was to describe an
approach to modeling the efﬁciency of an intervention by
focusing on an established intermediate end point directly.
A case study addresses the economic efﬁciency of obtain-
ing dual glycemic control over time, according to initial
choice of treatment.
Methods: From the perspective of a payer in the United
States, instead of the usual approach of basing the model
on projecting long-term diabetic complications from gly-
cemic control, this model focuses directly on glycemic
control. Treatment changes and associated health-care
utilization needed to address postprandial glucose. After
assigning each of 10,000 drug-naïve patients, HbA1c, age,
race, and sex based on distributions from a randomized
clinical trial, the model applies the efﬁcacy of nateglinide
compared to metformin. Sensitivity analyses were carried
out for all parameters. Costs are reported in year 2000 US
dollars and discounted at 3%.
Results: In the base case, starting on nateglinide and
increasing the time in dual glycemic control over 3 years
by 2.4 months led to savings of US $295 compared to
starting on metformin. Savings increased with stricter
treatment criteria but decreased if glycemic control was
better initially.
Conclusions: This study illustrates the use of an efﬁciency
model that focuses directly on the relevant short-term end
point: glycemic control. Starting patients with nateglinide
is shown to be an efﬁcient way of obtaining dual glycemic
control during the ﬁrst 3 years of treatment.
Keywords: modeling, diabetes, glycemia, economic.
Introduction
For most chronic diseases, it is not practical to
repeatedly conduct studies that quantify the effects
of treatments on the long-term outcomes that are
ultimately of interest. Although it is usually those
very outcomes that are the reason for treatment, the
time and effort required and the lack of timeliness
of the resulting information tend to be prohibitive.
Moreover, to monitor the disease and treatments in
actual practice, clinicians need measures that reﬂect
the long-term prognosis but are obtainable in the
real time of practice and are sensitive enough to
guide therapy. Accordingly, an indicator of thera-
peutic effect has been developed in most chronic
diseases. This indicator is distinguished by strong
prognostic ability in absolute terms: the capacity to
reﬂect risk changes owing to modiﬁcations in value,
though often unproven, sensitivity to treatment,
and relative ease of measurement. The lipid proﬁles,
glycemic levels, blood pressure, and the mini-mental
status exam are all examples.
For obvious reasons, clinical trials tend to use
these intermediate indicators as the primary end
points. For economic modeling these are viewed
as problematic, however. Cost-effectiveness ratios
expressed in terms of cost per unit change in an
intermediate indicator are not comparable among
diseases and are not even very meaningful within a
speciﬁc disease area. Thus, the tendency has been to
use their predictive ability to “translate” the short-
term results of the trials to meaningful long-term
outcomes. These types of models, however, are
fraught with difﬁcult-to-support assumptions,
extend well beyond the time horizons of relevance
to most decision-makers—both clinical and admin-
istrative—and go counter to developing regulatory
opinion that claims regarding health outcomes that
have not been studied should not be “created” by a
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model. Thus, although technically reasonable and
interesting, these long-term prediction models may
not have the authority to inform decisions and
hence the weight to signiﬁcantly sway those who
take them.
In this article, we describe a different approach
that, although not entirely novel, has not been com-
monly used. Rather than projecting the intermedi-
ate indicator values over the long term, we suggest
that they themselves be the focus—just as they are
in actual clinical practice. To avert meaningless out-
comes, however, we avoid building what amount to
simply short-term versions of the long-term models.
Instead, we think that the short-term model should
examine the efﬁciency of getting patients to the tar-
get values of the indicator: what proportion
achieves the goal in the near term, how long do they
stay at goal, what does it take to get them there, and
how much does it cost? The outcomes are compared
between current management where the new drug
or intervention is not available and what it would
be like if it were offered. These efﬁciency models
must allow for realistic treatment changes and
should try to reﬂect actual practice. Accordingly,
they should be ﬂexible to permit custom application
to a given setting. We illustrate this type of model
with an example from diabetes.
Methods
The Example
Type 2 diabetes is a serious, prevalent chronic dis-
ease that comprises more than 90% of the estimated
15 million diabetes cases identiﬁed in the United
States [1–3]. Because most of its devastating health
and economic [4–9] impact is a direct result of
hyperglycemia, the cornerstone of therapy is glyc-
emic control. Current guidelines of the American
Diabetes Association (ADA) recommend the use of
glycosylated hemoglobin (HbA1c) to monitor this
control [10] and physician adherence to these clin-
ical practice guidelines is growing [11]. This is
important because it has been shown that an
increase of 1% in HbA1c is associated with a 28%
increase in the risk of death independent of age,
blood pressure, serum cholesterol, body mass index,
and cigarette smoking in men with diabetes [12].
Moreover, it has been established that achieving
reductions in HbA1c decreases the risk of microvas-
cular complications [13,14,15].
Recently, the ADA recommended including post-
prandial glucose (PPG) monitoring as well [16],
based on growing evidence of the association
between PPG and macrovascular complications
[16–20]. Therefore, new therapies that modify PPG
and thereby reduce HbA1c, such as the recently
introduced nateglinide, could be valuable for meet-
ing the challenge of improving the management of
diabetes [21].
The insulin secretagogue nateglinide (Starlix®) is
effective in controlling PPG and reducing HbA1c
[22,23]. It has been approved for use in the United
States as monotherapy or in combination with other
drugs [23]. Like all new drugs entering the market,
it is important to assess not only its health beneﬁts,
but also its economic implications. Previous eco-
nomic models in diabetes have focused on long-
term complications [5,7,8,24,25], but these require
numerous assumptions and do not address the clin-
ically important issue of the efﬁciency with which it
can bring patients to target levels in the near term.
Therefore, a short-term efﬁciency model was devel-
oped to examine the direct medical costs of manag-
ing type 2 diabetes, according to the initial choice of
treatment based on the notion that it is desirable to
attain dual (both HbA1c and PPG) glycemic control.
Efﬁciency Model
Structure. The model (Fig. 1) is a discrete event sim-
ulation of the therapeutic process aimed at gaining
dual glycemic control. The model considers four
main health states: glycemic control, uncontrolled
glycemia, failure of oral therapy, and death. Dual
glycemic control is deﬁned in terms of both HbA1c
and PPG, according to the ADA guidelines. Uncon-
trolled glycemia occurs when either measure is out-
side the range speciﬁed in the guidelines. Failure is
deﬁned as persistent lack of glycemic control with
combination therapy. The model estimates the pro-
portion of patients achieving dual control at various
points in time as well as the costs of getting patients
Figure 1 Schematic representation of  the US diabetes economic
model.
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to that goal. Time is advanced in monthly ﬁxed
increments within a maximum time frame of
3 years. Random sampling of prespeciﬁed distribu-
tions is used to assign patient characteristics and to
simulate the management of each individual.
The model starts with a patient whose diabetic
state is deﬁned by an HbA1c value sampled from a
distribution. This derivation is based on regression
equations that take into account the baseline value,
the direction of change, and the type of treatment
in patients who failed dietary treatment and who
received antidiabetics for ﬁrst time (“drug naïve”).
Age, race, and sex are also assigned by weighted
random sampling of distributions [23]. These char-
acteristics help determine cholesterol, smoking sta-
tus, body mass index, and systolic blood pressure
values, all of which are sampled from conditional
distributions [26,27]. These attributes play a role in
longer-term simulations but not in the analyses car-
ried out here.
The management of this patient, along with
resulting changes in glycemic control, is then simu-
lated under a current treatment strategy and in one
where the new drug is available and used ﬁrst. For
each initial treatment, the resulting HbA1c is calcu-
lated and referred to a desired range to determine if
control has been achieved. Flexibility was built in to
permit the use of different guidelines (e.g., ADA,
Joslin Clinic) for determining control. If HbA1c con-
trol (HbA1c £ 8.0%, according to the ADA guide-
lines) is attained, it is assumed, consistent with
current practice, that this measure is given more
importance and thus outweighs PPG control; the
model considers the PPG by applying the treatment-
speciﬁc probability of reducing PPG to the desired
range. If dual control is achieved, then treatment
with the same drug(s) is continued at the same
dose(s) and the implications of dual control are tal-
lied. For these analyses, the implication is that the
physician visit rate is changed to every 6 months. If
the PPG is not controlled, then the implications of
lack of dual control are tallied (time with uncon-
trolled glycemia is incremented) but treatment is
continued unchanged (i.e., the model assumes that
current practice is not to make changes in treatment
if HbA1c is under control).
If the HbA1c is not controlled according to the
guidelines in force, or if it increased because
response to treatment was altogether negative, then
the model considers whether the HbA1c has
reached the level required to take action—a level
also determined according to the chosen guideline,
ADA for the base case [32]. If it has not reached
that level, the treatment continues unchanged but
the implications of no control are tallied; time with
uncontrolled glycemia is incremented. If the HbA1c
level indicates a need for treatment change,
the next therapeutic action in a predetermined
sequence is considered at the time of the next visit
to the health-care provider. This may include a
titration to a higher dose, an addition of another
drug or a switch to another drug depending on
what treatment the patient has been on, and how
many visits with uncontrolled glycemia have
occurred. The model also allows for imperfect clin-
ical action either in detection of the lack of control
or in taking action, but in the analyses presented
here it is assumed that practice is optimal in this
regard. The implications of the treatment change
are then tallied. Before proceeding to the next
monthly cycle, if there has been no treatment
change, the model applies upward drift to the
HbA1c based on the results observed in the UKPDS
study [28–30]. If the treatment has changed, then
the effect of that treatment is applied using the
same technique (though different, treatment-
speciﬁc equations) as for the initial treatment. At
the start of each monthly cycle, the model checks
whether the simulated patient has survived to that
point. The risk of death was obtained by adjusting
the general age- and sex-dependent mortality haz-
ard by the relative risk associated with diabetes
[31]. It was assumed that over the short term,
treatment did not change this hazard.
The assumptions made in developing the treat-
ment pathways and determining the resource use
and costs associated with the algorithms in each
arm of the model were tested using an expert panel
of seven physicians (two endocrinologists, two
internists, and three family physicians), who con-
curred with them [1].
Default Inputs. There were two types of inputs
speciﬁed: one applied to all treatments compared
and the other particular to each treatment. The gen-
eral set of inputs involved the distributions of initial
HbA1c, age, race, and sex; the mortality hazard
equations; the frequency of physician visits accord-
ing to the patient’s status; the criteria for consider-
ing control and treatment changes; the upward drift
in HbA1c; the unit costs and resource use proﬁles
(for physician visits, laboratory tests, and other
studies); and the discount rate. The treatment-
speciﬁc inputs involved dosing, efﬁcacy in terms
of lowering the HbA1c and in terms of bringing
the PPG within the controlled range, the risk of
hypoglycemia, any additional monitoring, and drug
costs.
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For the base case, the distribution of initial
HbA1c, age, sex, and race were obtained from a ran-
domized clinical trial that compared nateglinide to
metformin monotherapy and the combination of
the two [23]. There were 3.4% of patients whose
HbA1c was 8.0, 45.9% between 8.1 and 9.0, 36.2%
from 9.1 to 10.0, 12.9% from 10.1 to 11.0, and
1.6% above that. The proportion of men was
62.2%, and 80.6% of patients were white whereas
11.8% were black, 1.6% were Asian, and 6% were
other. The mean age was 58.3 ± 10.9 years
(Table 1).
The routine frequency of physician visits was
assigned to each patient based on a distribution that
allowed for practice variations. Base case analyses
used the ADA guidelines [32] that patients should
be seen at least quarterly until achievement of treat-
ment goals. Once a patient reaches glycemic
control, it was assumed that the visit frequency
decreased to biannual. A visit was also assumed to
take place when the dose was titrated up or when
treatment was changed. In the base case, the cutoff
points to consider HbA1c controlled or to take an
action were deﬁned using the ADA guidelines:
≤7.0% for control and ≥8.0% to change treatment.
From 7.0% to 8.0%, glycemia was considered nei-
ther controlled nor high enough to warrant action.
In sensitivity analyses, the criteria of the Joslin
Clinic, which require a tighter glycemic control
(7.5% to take action compared to 8.0% of ADA),
were used. As observed in the UKPDS [28–30], it
was estimated that the HbA1c would drift upward
on average 0.15% per year.
To reﬂect the direct economic burden of diabetes
management from the perspective of a comprehen-
sive health-care payer, we considered costs associ-
ated with the drugs, medical doctor visits, other
professional services (e.g., dietician), laboratory
tests, and home monitoring supplies. In the base
case, the laboratory testing proﬁles at the annual
visit and at monitoring visits were based on the rec-
ommendations made in the ADA guidelines [32]
and set identically for all treatments, except insulin,
which was assumed to incur an additional electro-
cardiogram annually. Unit costs were obtained
from national fee schedules [33], the Redbook [34],
and other published data. The unit costs for moni-
toring visits included a urine dipstick ($4.35), a
fasting plasma glucose ($5.41), and an HbA1c deter-
mination ($13.23) [33]. For the annual visit, a lipid
panel ($17.98), a test for albumin in urine ($5.47),
a plasma albumin ($7.69), a plasma creatinine
($7.05), and a basic metabolic proﬁle ($11.34)
were added [33]. The cost of a regular physician
visit for monitoring was set at $33.19 and for the
annual comprehensive visit at $53.69; for a dieti-
cian the annual visit was set at $48.48; the cost of a
monitoring visit, including all the laboratory tests
and professional fees, was $62; and the annual
comprehensive visit was $176. The unit cost of
metformin was based on the average wholesale
price: $0.65 for 500-mg tablets, $1.09 for 850-mg
tablets, and $1.33 for 1000-mg tablets [34]. The
unit cost for nateglinide was $0.96 per 120-mg tab-
let. For the combination, the cost was the sum
($4.83). All costs are reported in year 2000 US dol-
lars (no adjustment for medical inﬂation was neces-
sary). Discounting (3% per year) was applied to the
costs and to time in control that accrued beyond
the ﬁrst month.
Treatments Compared
In these analyses, efﬁcacy data from the nateglinide
clinical trial were the basis for comparison of
nateglinide with metformin monotherapy as initial
choices patients with type 2 diabetes. The base case
examined 120 mg nateglinide and 500 mg met-
formin, both three times daily. Metformin can be
increased progressively up to 2550 mg per day with
titrations every 2 weeks, according to the HbA1c
levels.
For both treatments, the ﬁrst treatment change,
other than titration, was to the combination of
120 mg nateglinide and 500 mg metformin taken
three times daily. If combination treatment failed,
Table 1 Inputs for the base case analyses
Parameter Base case
Age, years (%)
29–40 5.3
41–52 24.5
53–64 41.0
65–76 25.3
>77 3.9
Men (%) 62.2
Ethnicity
White 80.6
Black 11.8
Hispanic 3.0
Asian 1.6
Natives 3.0
Mean HbA1c
Initial (%) 8.2
Upward drift (%/year) 0.15
Mean decrease in HbA1c level
Monotherapy -0.82
Combination -2.13
Mean initial 2-hour PPG (mg/dl) 141.50
Guidelines American Diabetes Association
Model time horizon (years) 3
Discount rate (%) 3
Physician visit, routine rate One visit/quarter
Nateglinide price (cost/day) $2.88
Metformin price $1.95
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then the next change was to insulin, which was con-
sidered a “failure,” although the costs continued to
accrue.
Hypoglycemia was the only side effect consid-
ered, based on the trials [23]: 0.46 conﬁrmed epi-
sodes per patient-month with nateglinide and 0.16
with metformin. Given that no severe episodes
requiring medical intervention occurred, the cost
consisted only of the use of one extra glucose strip
and the glucometer, $2.48.
Analyses
The main measure of effectiveness was the time in
dual control and the proportion of patients achiev-
ing the dual control. Other outcomes included were
time spent on each treatment, number of physician
visits, number of treatment changes, cumulative
costs after 3 years, and costs by type of resource.
Incremental cost per month with dual control was
also calculated, where appropriate. Sensitivity anal-
yses were performed for all model parameters and
various combinations of these.
Results
Base Case
In the base case, the patients stayed on mono-
therapy for 27 months, on average; 14% eventually
required combination therapy, and 19% switched
to insulin. Patients starting on nateglinide had an
additional 2.5 months with dual control (17.8
months compared to 15.3 months with initial met-
formin) and only 11.6 physician visits compared to
16.4. Metformin leads to an average 3-year cost of
$5826 per patient—the majority attributable to the
drug itself (73%). Patients who achieved control on
the initial dose of metformin were the least expen-
sive (mean $5321). Nateglinide resulted in an aver-
age cost of $5531 (Fig. 2). Thus, nateglinide would
be expected to be more efﬁcient at attaining thera-
peutic goals by increasing the time with dual control
and reducing costs in doing so. In this context, an
incremental cost-effectiveness ratio was not calcu-
lated. The average cost-effectiveness ratio (i.e., com-
pared to no treatment at all) for nateglinide was
$311 per month with dual control compared to
$379 for metformin.
Sensitivity Analyses
Extensive sensitivity analyses were carried out and
the results are summarized in Figure 3. The HbA1c
cutoff point to take an action is a key input: with
the stricter Joslin Clinic guideline, the number of
treatment changes, as well as physician visits,
increases for both treatments but the savings with
nateglinide grow to $487 because of fewer titra-
tions. If titration required a physician visit only
every other titration, the savings with nateglinide
would drop to $166, and if no visits were required,
the costs would increase to a net of $61, producing
an incremental cost-effectiveness ratio of $17 per
additional month with dual control (Table 2). In
patients with borderline elevations of initial HbA1c
(6% and 7%), metformin had lower net costs
because more patients remained on the lowest dose
without having to titrate up. In contrast, patients
with initial HbA1c greater than 8.0% had better
results with nateglinide.
Figure 2 Total costs at the end of  3-year period by components for
patients with initial HbA1c of  8.0.
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Discussion
In this article, we present an approach to economic
modeling of a chronic disease based on established
intermediate end points. This approach has the
advantages of requiring fewer assumptions; making
no projections over long periods of time; focusing
on end points of direct relevance to clinicians,
patients, and administrators; and not creating efﬁ-
cacy purely as a result of the model itself. Thus,
this kind of model accords with the clinical trial
evidence that is usually available—it makes no
demands for data that will not be available for a
long time, if ever—and should be able to inform
decisions about management of the disease in real
time and actual practice.
There are some important drawbacks to this
approach. Though highly practical and relevant, it
is not entirely in agreement with current guidelines
for economic analyses of health-care interventions
[35]. In particular, it deliberately fails to extend the
time horizon “long enough to reﬂect important
and valued differences between the long-run conse-
quences and costs . . .” This, in turn, means that the
results that it produces are not comparable with
those of the models that do engage in long-term pre-
dictions and, thus, those benchmarks (e.g., $50,000
per QALY gained) are meaningless and compari-
sons with other health care interventions may be
difﬁcult or impossible. Moreover, by failing to
extend the time horizon to cover long-term conse-
quences, important savings that may help justify the
intervention, or costs that may bury it, are ignored.
It is our contention, however, that these disadvan-
tages pale beside the pragmatic value of this type of
model to actual decision-makers concerned with
providing quality care consistent with extant clini-
cal guidelines. In this situation, meeting short-term
goals is exactly what is sought, and evaluating the
efﬁciency of doing so is the issue.
In these analyses, the early management of type 2
diabetes to address the efﬁciency with which vari-
ous treatment strategies achieve glycemic control, in
terms of both HbA1c and PPG, consistent with cur-
rent guidelines. Given the growing appreciation of
the relation of glycemic control to the occurrence of
macrovascular and other diabetic complications,
one may question the period of time covered in the
model, but meeting short-term treatment objectives
for patients with type 2 diabetes is a prerequisite for
successful reduction of complications. This model
had some limitations apart from the short time hori-
zon. The total costs have been underestimated as
hospitalizations are not included, but this is con-
servative because it reduces the advantage of attain-
ing glycemic control faster. Another limitation is
that diabetes management is driven by current
guidelines—it is possible that less aggressive or
consistent approaches exist in actual practice. The
effect of such variations on the comparative results
is unclear and while they may lower short-term
costs, they will also lead to poorer control. Further-
more, hypoglycemia was the only adverse event
included; yet gastrointestinal events are more fre-
quent with metformin [23]. Therefore, it is possible
that we underestimated the costs of metformin
treatment.
Over the 3 years modeled, these patients are pre-
dicted to remain on monotherapy the majority of
the time. This is consistent with the results reported
by the UKPDS, where at the end of 3 years, 76% to
81% of patients were still receiving monotherapy
[36]. The costs of diabetes management over these
3 years were approximately $5000 per patient,
depending on the level of glycemic control and
other factors. Other studies [9,37] have found sim-
ilar costs.
The insulin secretagogue nateglinide is predicted
to increase dual control while leading to a savings
of about $300. Improving glycemic control has
been shown in other studies to decrease costs. One
cohort study showed that costs increased signiﬁ-
cantly for every percentage point increase above an
HbA1c of 7% [38], and another [39] found that the
charges went from $970 in those with good con-
trol to $1380 with fair control and $3040 with
poor control. This relationship of cost to glycemic
control was conﬁrmed in another recent study
Table 2 Parameter varied in the sensitivity analyses
Parameter Sensitivity range
Results
Net cost Net time in control
Initial HbA1c(%) 6 to 11 $847 to $-433 4.0–1.5
Joslin Clinic guidelines $-487 2.0
Discount rate (%) 0, 5 $-300, $-292 2.1, 2.1
Physician visit rate No visit for metformin/month $61 3.7
Nateglinide price -25% to +100% $-986 to $2466 2.4, 2.4
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[40]. Indeed, in our model, patients who achieved
dual control on monotherapy were the least expen-
sive to manage. The savings with nateglinide were
higher in patients who started with worse control
and attenuate when initial glycemia was near nor-
mal. This is not surprising because the model
“enforces” action when glycemic control is poor
and these actions have a cost; but this is consistent
with the idea that the decision-maker wants opti-
mal practice.
The focus of this model on both HbA1c and PPG
in the short term is novel. Previous guidelines and
recommendations advise monitoring fasting plasma
glucose (FPG) and HbA1c [32]. FPG, however, does
not address the contribution of the postprandial rise
in glucose to overall control, and HbA1c does not
address the daily oscillations in glucose, because it
only reﬂects average glycemia [41,42]. We added
PPG to the criteria for glycemic control because the
treatment goal for patients with type 2 diabetes
should be to achieve the best possible glycemic
control by restoring a normal, physiologic insulin
response to feeding and by decreasing late postpran-
dial insulin levels and chronic hyperinsulinemia
[43]. In addition, PPG levels may more closely
reﬂect the metabolic processes involved in the
pathogenesis of type 2 diabetes—increased hepatic
glucose output, impaired insulin secretion, and
insulin resistance [44,45]. Indeed, several studies
have shown a better correlation between 2-hour
PPG and the risk of cardiovascular disease [43,46–
50] and atherosclerosis risk factors [51] than with
either FPG or HbA1c.
This case study illustrates the modeling of efﬁ-
ciency of reaching a target intermediate end point
and indicates that starting drug-naïve patients on
nateglinide is an efﬁcient way of obtaining dual gly-
cemic control during the ﬁrst 3 years of treatment.
The authors acknowledge Tara Markley’s support in run-
ning the model.
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